JP Morgan Moves Alexion Pharma To Overweight, Says Strensiq And Kanuma Are $1.7B Opportunity

By: via Benzinga
In a report published Monday, JP Morgan analyst Anupam Rama upgraded the rating on Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) from ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.